{
    "guideline": {
        "id": "PA166222801",
        "name": "Annotation of DPWG Guideline for flucytosine and DPYD",
        "source": "DPWG",
        "version": 11,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166222801",
        "relatedChemicals": [
            {
                "id": "PA449654",
                "name": "flucytosine",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA145",
                "name": "dihydropyrimidine dehydrogenase",
                "symbol": "DPYD"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166299164",
            "name": "Recommendation PA166299164",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061527,
                "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur</li>\n</ul>\n</li>\n</ul>\n"
            },
            "implications": [
                "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to react to fluorouracil, but generally tolerate low doses (approximately 50% of the standard fluorouracil dose)."
            ],
            "lookupKey": {
                "DPYD": "1.0 (Intermediate Metabolizer)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166301782",
            "name": "Recommendation Annotation PA166301782",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452102461,
                "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea.\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
            },
            "implications": [
                "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (15-50% of the standard fluorouracil dose)."
            ],
            "lookupKey": {
                "DPYD": "1.0 (Phenotyping)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166299163",
            "name": "Recommendation PA166299163",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061526,
                "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
            },
            "implications": [
                "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (50-75% of the standard fluorouracil dose)."
            ],
            "lookupKey": {
                "DPYD": "1.5 (Intermediate Metabolizer)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166299162",
            "name": "Recommendation PA166299162",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061525,
                "html": "<p>The guideline does not provide a recommendation for flucytosine in patients with a DPYD activity score of 2.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a DPYD activity score of 2 on flucytosine."
            ],
            "lookupKey": {
                "DPYD": "2.0 (Normal Metabolizer)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166299160",
            "name": "Recommendation PA166299160",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061523,
                "html": "<p>Avoid flucytosine</p>\n"
            },
            "implications": [
                "A risk of life-threatening toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil and patients with this gene variation are intolerant even to small quantities of fluorouracil."
            ],
            "lookupKey": {
                "DPYD": "0.0 (Poor Metabolizer)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166299161",
            "name": "Recommendation PA166299161",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449654",
                    "name": "flucytosine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061524,
                "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea.\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
            },
            "implications": [
                "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (15-50% of the standard fluorouracil dose)."
            ],
            "lookupKey": {
                "DPYD": "0.5 (Phenotyping)"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        }
    ],
    "citations": [],
    "version": "2024-03-25-16-13"
}